Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.

MLA

Spohn, Simon K. B., et al. “Development of PSMA-PET-Guided CT-Based Radiomic Signature to Predict Biochemical Recurrence after Salvage Radiotherapy.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 50, no. 8, July 2023, pp. 2537–47. EBSCOhost, https://doi.org/10.1007/s00259-023-06195-3.

APA

Spohn, S. K. B., Schmidt-Hegemann, N.-S., Ruf, J., Mix, M., Benndorf, M., Bamberg, F., Makowski, M. R., Kirste, S., Rühle, A., Nouvel, J., Sprave, T., Vogel, M. M. E., Galitsnaya, P., Gschwend, J. E., Gratzke, C., Stief, C., Löck, S., Zwanenburg, A., Trapp, C., & Bernhardt, D. (2023). Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy. European Journal of Nuclear Medicine & Molecular Imaging, 50(8), 2537–2547. https://doi.org/10.1007/s00259-023-06195-3

Chicago

Spohn, Simon K. B., Nina-Sophie Schmidt-Hegemann, Juri Ruf, Michael Mix, Matthias Benndorf, Fabian Bamberg, Marcus R. Makowski, et al. 2023. “Development of PSMA-PET-Guided CT-Based Radiomic Signature to Predict Biochemical Recurrence after Salvage Radiotherapy.” European Journal of Nuclear Medicine & Molecular Imaging 50 (8): 2537–47. doi:10.1007/s00259-023-06195-3.